As previously reported, Cantor Fitzgerald initiated coverage of Vaxcyte (PCVX) with an Overweight rating and no price target Vaxcyte was hit with the combination of mixed VAX-24 pediatric data and an increasingly clear shift in U.S. vaccine policy emerging from new government leadership, says the analyst, who says “leadership, administrations, and priorities will ultimately change,” but the $8B-plus PCV market opportunity remains attractive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte initiated with an Overweight at Cantor Fitzgerald
- Biotech Alert: Searches spiking for these stocks today
- Vaxcyte’s Promising Prospects: Buy Rating Reinforced by Positive Phase 2 Data and Strategic Expansion
- Optimistic Buy Rating for Vaxcyte Amid Vaccine Development Challenges and Strategic Adjustments
- BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’